Skip to main content
Fig. 1 | BMC Medicine

Fig. 1

From: Association between progression-free survival and overall survival in women receiving first-line treatment for metastatic breast cancer: evidence from the ESME real-world database

Fig. 1

Study flow chart

ESME, epidemiological strategy and medical economics; mBC, metastatic breast cancer; HR + , presence of hormone receptor; HR − , absence of hormone receptor; HER2 + , human epidermal growth factor receptor 2 (HER2) protein overexpression; HER2 − , no HER2 protein overexpression. TN, triple negative

Back to article page

BMC Medicine

ISSN: 1741-7015

Contact us